CN110505885A - 寡聚体延伸的胰岛素-Fc缀合物 - Google Patents

寡聚体延伸的胰岛素-Fc缀合物 Download PDF

Info

Publication number
CN110505885A
CN110505885A CN201880023755.XA CN201880023755A CN110505885A CN 110505885 A CN110505885 A CN 110505885A CN 201880023755 A CN201880023755 A CN 201880023755A CN 110505885 A CN110505885 A CN 110505885A
Authority
CN
China
Prior art keywords
insulin
conjugate
human insulin
amino group
desb30 human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201880023755.XA
Other languages
English (en)
Chinese (zh)
Inventor
T.M.塔格莫斯
P.玛德森
T.B.克尔森
L.普利达尔
L.德玛利亚
林兆生
万哲
张媛媛
L.利克
M.W.B.蒙泽尔
J.T.柯德拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN110505885A publication Critical patent/CN110505885A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201880023755.XA 2017-04-05 2018-04-04 寡聚体延伸的胰岛素-Fc缀合物 Withdrawn CN110505885A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP17164950 2017-04-05
EP17164950.2 2017-04-05
EP17208780.1 2017-12-20
EP17208780 2017-12-20
EP18151228 2018-01-11
EP18151228.6 2018-01-11
CN201810276163 2018-03-30
CN2018102761630 2018-03-30
PCT/EP2018/058550 WO2018185131A2 (en) 2017-04-05 2018-04-04 Oligomer extended insulin-fc conjugates

Publications (1)

Publication Number Publication Date
CN110505885A true CN110505885A (zh) 2019-11-26

Family

ID=61868527

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880023755.XA Withdrawn CN110505885A (zh) 2017-04-05 2018-04-04 寡聚体延伸的胰岛素-Fc缀合物

Country Status (6)

Country Link
US (1) US11471537B2 (https=)
EP (1) EP3606560A2 (https=)
JP (1) JP2020513019A (https=)
CN (1) CN110505885A (https=)
MA (1) MA49339A (https=)
WO (1) WO2018185131A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025098472A1 (zh) * 2023-11-08 2025-05-15 北京拓界生物医药科技有限公司 融合蛋白及其医药用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
US20210188895A1 (en) * 2017-10-13 2021-06-24 Bonac Corporation Single-stranded nucleic acid molecule, and production method therefor
WO2020074544A1 (en) * 2018-10-10 2020-04-16 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use
BR112021005320A2 (pt) * 2018-12-17 2021-06-15 Remegen Co., Ltd. ligante para conjugados de anticorpo-fármaco e seu uso
CN111217915B (zh) * 2019-01-08 2021-05-14 东莞太力生物工程有限公司 GLP-1类似物Fc融合多肽及其应用
CN113968911B (zh) * 2020-07-24 2023-10-10 江苏晟斯生物制药有限公司 胰岛素-Fc融合蛋白及其应用
WO2023064711A2 (en) * 2021-10-14 2023-04-20 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI871539B (zh) 2021-11-15 2025-02-01 美商美國禮來大藥廠 可保存之調配物
JP2025522529A (ja) * 2022-06-23 2025-07-15 サノフイ 一本鎖インスリン及びそのＦｃ結合体
CN115947822B (zh) * 2022-07-04 2023-08-18 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其药物组合物和应用
JP2026031900A (ja) * 2024-07-24 2026-02-25 イーライ リリー アンド カンパニー Ｆｃ－アシル化ポリペプチドコンジュゲート
CN118955627B (zh) * 2024-10-17 2025-02-07 山东华涛食品有限公司 一种混合型抑制α-葡萄糖苷酶活性的甘薯肽组合物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869371A (zh) * 2010-04-02 2013-01-09 韩美科学株式会社 使用免疫球蛋白片段的胰岛素缀合物
US20160000932A1 (en) * 2005-08-12 2016-01-07 Amgen Inc. MODIFIED Fc MOLECULES
WO2016133372A2 (ko) * 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
WO2016178905A1 (en) * 2015-05-07 2016-11-10 Eli Lilly And Company Fusion proteins
WO2016193380A1 (en) * 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
CN106459171A (zh) * 2014-02-28 2017-02-22 诺和诺德股份有限公司 A22K,desB27,B29R,desB30,在赖氨酸22的ε位置处被酰化的人胰岛素类似物
WO2017031034A2 (en) * 2015-08-14 2017-02-23 Rc Biotechnologies, Inc. Covalent linkers in antibody-drug conjugates and methods of making and using the same

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE257197C (https=)
DE286509C (https=)
US3914252A (en) 1971-03-15 1975-10-21 Continental Oil Co Preparation of N-iodocompounds
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DK0851925T3 (da) 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
AU5065198A (en) 1996-11-15 1998-06-10 Maria Grazia Masucci Fusion proteins having increased half-lives
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US7754855B1 (en) 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
AU2002219021A1 (en) 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
US20020169125A1 (en) 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
EP1444262A2 (en) 2001-11-12 2004-08-11 University of Wales College of Medicine Growth hormone variations in humans and their uses
GB2384001B (en) 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2383300T3 (es) 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
KR100594607B1 (ko) 2004-11-03 2006-06-30 재단법인서울대학교산학협력재단 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
BRPI0606934A2 (pt) 2005-01-25 2017-07-11 Cell Therapeutics Inc Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
JP2008528549A (ja) 2005-01-27 2008-07-31 ノボ ノルディスク アクティーゼルスカブ 構造的に充分に定義された分岐ポリマーと接合されたインスリン誘導体
CA2601745A1 (en) 2005-02-16 2006-08-24 Novo Nordisk A/S Insulinotropic agents conjugated with structurally well defined branched polymers
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CN101330931B (zh) 2005-12-12 2012-09-05 创新生物科学有限公司 制备缀合物
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
AU2007223855B2 (en) 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
WO2008052108A2 (en) 2006-10-26 2008-05-02 Centocor Ortho Biotech Inc. Methods for use in human-adapting monoclonal antibodies
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
KR20080095141A (ko) 2007-04-23 2008-10-28 포항공과대학교 산학협력단 인간 알부민 링커를 통하여 면역글로불린의 Ｆｃ에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법
ES2623925T3 (es) 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
EP2203180B1 (en) * 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
WO2009155513A2 (en) 2008-06-20 2009-12-23 Novartis Ag Immunoglobulins with reduced aggregation
WO2010001196A1 (en) 2008-07-02 2010-01-07 Koninklijke Philips Electronics N.V. V-spring configuration and end attachment assemblies therefor for use in a personal care appliance
MX2011000861A (es) 2008-07-23 2011-06-21 Hanmi Holdings Co Ltd Un complejo polipeptidico que consiste en un polimero no-peptidil que posee tres terminaciones funcionales.
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
WO2011028952A1 (en) * 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN104147611A (zh) 2009-09-30 2014-11-19 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
ES2622102T3 (es) 2009-10-29 2017-07-05 Janssen Biotech, Inc. Variantes de anticuerpo de glicosilación
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US9783571B2 (en) 2011-04-05 2017-10-10 Warham Lance Martin Isolation of cysteine containing peptides
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
JP6355563B2 (ja) 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド Ｘｔｅｎ共役組成物およびそれを製造する方法
CA2873112A1 (en) 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー／エス 成熟インスリンポリペプチドを作製するための方法
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
WO2015081073A2 (en) 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Compositions and methods for modulating an immune response
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
JP6783754B2 (ja) 2014-09-17 2020-11-11 ノヴォ ノルディスク アー／エス 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000932A1 (en) * 2005-08-12 2016-01-07 Amgen Inc. MODIFIED Fc MOLECULES
CN102869371A (zh) * 2010-04-02 2013-01-09 韩美科学株式会社 使用免疫球蛋白片段的胰岛素缀合物
CN106459171A (zh) * 2014-02-28 2017-02-22 诺和诺德股份有限公司 A22K,desB27,B29R,desB30,在赖氨酸22的ε位置处被酰化的人胰岛素类似物
WO2016133372A2 (ko) * 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
WO2016178905A1 (en) * 2015-05-07 2016-11-10 Eli Lilly And Company Fusion proteins
WO2016193380A1 (en) * 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
WO2017031034A2 (en) * 2015-08-14 2017-02-23 Rc Biotechnologies, Inc. Covalent linkers in antibody-drug conjugates and methods of making and using the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025098472A1 (zh) * 2023-11-08 2025-05-15 北京拓界生物医药科技有限公司 融合蛋白及其医药用途

Also Published As

Publication number Publication date
EP3606560A2 (en) 2020-02-12
US11471537B2 (en) 2022-10-18
MA49339A (fr) 2020-02-12
WO2018185131A3 (en) 2018-11-15
US20200261595A1 (en) 2020-08-20
WO2018185131A2 (en) 2018-10-11
JP2020513019A (ja) 2020-04-30

Similar Documents

Publication Publication Date Title
CN110505885A (zh) 寡聚体延伸的胰岛素-Fc缀合物
DK172456B1 (da) Lægemidler indeholdende insulinderivater til behandling af diabetes mellitus
CN104995206B (zh) 新颖的胰岛素类似物及其用途
TWI684458B (zh) 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
ES2985999T3 (es) Conjugados de proteínas
CN103596584B (zh) 多取代的胰岛素
KR101324828B1 (ko) 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
JP6336394B2 (ja) 生理活性ポリペプチド複合体の製造方法
EP3861017A1 (en) Bifunctional compounds comprising insulin peptides and egf(a) peptides
CN110339369B (zh) 制备生理活性多肽复合物的改进方法
KR20130036290A (ko) 추가 이황화 결합을 함유하는 인슐린 유도체
WO2016131893A1 (en) Incretin fusion polypeptides
CN111183148A (zh) Mic-1化合物及其用途
JP7752664B2 (ja) 新規な中間体製造による持続型薬物結合体の製造方法
US20210393745A1 (en) Oligomer extended insulin-fc conjugates and their medical use
KR20170104409A (ko) 폴리에틸렌 글리콜 유도체 및 이의 용도
CN108727486A (zh) 长效神经生长因子、制备方法及其组合物
JP2023538236A (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物
WO2017210168A1 (en) Aqueously soluble and chemically stable depsi glucagon agonists
JP2026031900A (ja) Ｆｃ－アシル化ポリペプチドコンジュゲート
CN115776880A (zh) 液体制剂
HK1235013A1 (en) Composition for treating diabetes mellitus comprising insulin and a glp-1/ glucagon dual agonist
HK1196373A (en) Method for preparing physiologically active polypeptide complex

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20191126

WW01 Invention patent application withdrawn after publication